Fortis

Biotec Pharmacon ASA (OSL:BIOTEC) (Tromsø/Oslo 30 October 2008) The bio-pharmaceutical company Biotec Pharmacon has now included more than 75 percent of the patients in the first of two phase III-studies with SBG for diabetic ulcers, and in October included the first patients in the first of two phase III-studies with SBG for oral mucositis. The company expects to commence patient enrolments in two further phase III-studies in the fourth quarter, and maintains its objective to apply for marketing authorizations in Europe mid-2010.

Biotec Pharmacon ASA (OSL:BIOTEC) Patient inclusion has commenced as planned in the first of two phase III studies for the use of Biotec Pharmacon's SBG in patients with oral mucositis. This is a common and potentially severe side-effect of radiotherapy for cancer, in particular for head and neck cancers. Biotec Pharmacon expect to start patient inclusion in a second phase III study of oral mucositis later in the fourth quarter, with a target to file for marketing applications for SBG for this indication mid-2010.

Biotec Pharmacon ASA (OSL:BIOTEC) Dr. Rohmann is a MD by training and has a Ph.D. in experimental cardiology. He is joining the company from Novartis Pharma AG, where he, as part of the Global Business Development & Licensing Team, was heading up the company's Venture Capital Fund activities.

Biotec Pharmacon ASA (OSL:BIOTEC) Oslo, 25 August, 2008: Biotec Pharmacon ASA has reached agreement on the sale of its wholly-owned Immunocorp Animal Health AS subsidiary to Brazil's Biorigin for NOK 37.5 million.

Biotec Pharmacon ASA (OSL:BIOTEC) Immunocorp Animal Health AS (IAH), a wholly owned subsidiary of Biotec Pharmacon ASA, has been awarded a major research and development contract by the European Commission. The contract will be undertaken by nine partners from Norway, the Netherlands, Denmark, England, Germany and Poland and is entitled "Training network on protective immune modulation in warm water fish by feeding glucans".The contract has been issued under the European Union's Seventh Framework Programme (FP7) for research and technological development and has a total remit of NOK 24 million (EUR 3 million) over four years. The research project will be based upon applications with the IAH glucan product MacroGard®. MacroGard® is currently sold as an ingredient in animal feed to strengthen the innate immune system. The research contract will enable the company to document new applications for MacroGard® and strengthen the brand as the world's best-documented glucan for use in animal f ...